COPD muscle loss: could blood cells be the culprit?
NCT ID NCT04939454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether specific cells from the blood, called fibrocytes, are involved in muscle wasting (sarcopenia) in people with COPD. Researchers compared thigh muscle samples from 22 COPD patients with and without muscle loss. The goal was to understand why muscle loss happens, which could lead to better treatments in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
22 people
The number who actually took part.
- Started
-
Nov 2022
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women 40 years of age or older; * Diagnosed with COPD according to the 2018 Global Initiative for Lung Disease (GOLD) criteria: * Smoking intoxication greater than or equal to 10 pack-years * Bronchial obstruction on spirometry with a FEV1 to FVC ratio post-bronchodilator \< 70%. * Available measurement of lean body mass by bioelectrical impedancemetry performed as part of routine care; * Insured under the French social security system; * Informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). The patients included will be sarcopenic and non-sarcopenic (equal numbers in each group, patients categorized according to the result of dexametry), and will be matched on sex and age (± 5 years). Exclusion Criteria: * Other concomitant respiratory pathology (e.g., asthma); * Acute exacerbation of COPD or acute intercurrent condition (e.g. infection) ongoing or resolved within the last 48 hours * Current systemic corticosteroid therapy; * Contraindication to muscle biopsy: acquired or innate hemostasis disorders, anticoagulant therapy or double anti-platelet aggregation; contraindication to lidocaine: known hypersensitivity, patients with recurrent porphyrias; * Presence of a concomitant muscular pathology, innate (e.g. genetic myopathy) or acquired (e.g. myositis); * Progressive bronchopulmonary cancer; * Pregnant or breast-feeding woman; * Patient undergoing respiratory rehabilitation; * Refusal to participate in the study. Exclusion criteria between V1 and V2: * Disorders of hemostasis detected on the blood sample; * Pregnancy in progress.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary disease, chronic obstructive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Haut-Lévêque - CHU de Bordeaux
Pessac, 33600, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.